2026 Critical Care Congress Skip to main content
2026 Critical Care Congress Main banner
Final Program


Advance Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Thought Leader Session
Thought Leader Session
Guidelines Session
Guidelines Session
Aging Adult Track
Aging Adult Track
Additional Registration Fee
Additional Registration Fee

Michelle Hoffman (she/her/hers)

Michelle Hoffmann, Ph.D. has been serving since August of 2021 as the Executive Director of the Chicago Biomedical Consortium (CBC) and the CBC Hub for Innovative Technology and Entrepreneurship in the Sciences (CBC-HITES), a consortium of biomedical researchers across Northwestern, the University of Illinois at Chicago, the University of Chicago, the University of Illinois Urbana Champaign, Illinois Institute of Technology, Loyola University Chicago, Northern Illinois University, Rosalind Franklin University, and Rush University. The Consortium is generously supported by the Searle Funds at The Chicago Community Trust, the National Institutes of Health, and the Walder Foundation.

CBC/ CBC-HITES’s aim is to find, fund, and translate the best biomedical research across these nine research institutions by embedding industry expertise and resources at the academic level. In her time as Executive Director, Dr. Hoffmann has reorganized the CBC to train local PhD talent in the business of early science commercialization while developing a process to find and fund the most promising biopharma applications of Chicago university science. Before this role, from 2019-2021, Dr. Hoffmann was the Senior Vice President of Deep Tech at P33, a privately funded nonprofit charged with elevating Chicagoland’s innovation economy and driving inclusive economic growth.

Prior to her economic development and nonprofit work, Hoffmann spent 15 years helping life sciences companies grow, most recently as a senior vice president at Boston-based Back Bay Life Science Advisors, an integrated strategy and investment firm to global life science companies and their investors. During her time at Back Bay, Hoffmann led projects for large, publicly traded companies, as well as small, private, venture-backed health care and life sciences companies. Hoffmann earned a PhD in molecular and cellular biology from the University of California Berkeley and completed a postdoctoral fellowship at Brandeis University.

Presentation(s):